Literature DB >> 11879679

Poly(ADP-ribose) polymerase: killer or conspirator? The 'suicide hypothesis' revisited.

Alberto Chiarugi1.   

Abstract

Poly(ADP-ribose) polymerase 1 (PARP-1) is an abundant nuclear enzyme involved in DNA repair. The therapeutic efficacy of drugs that inhibit PARP-1 in various disorders underscores the active role of PARP-1 in cell death. Although it is well established that excessive DNA damage causes PARP-1 hyperactivation, which leads to cell death by energy failure, a new mechanistic perspective is emerging following the identification of various PARPs that exhibit different features and subcellular distributions. Studies demonstrating the significant role of PARP-1 in the regulation of gene transcription have further increased the intricacy of poly(ADP-ribosyl)ation in the control of cell homeostasis and challenge the notion that energy collapse is the sole mechanism by which poly(ADP-ribose) formation contributes to cell death. The hypothesis that PARPs might regulate cell fate as essential modulators of death and survival transcriptional programs will be discussed with particular focus on the regulation of transcription factors such as nuclear factor kappaB and p53. (An animation depicting the involvement of PARP-1 in the 'suicide hypothesis' is available at http://archive.bmn.com/supp/tips/tips2303a.html)

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11879679     DOI: 10.1016/S0165-6147(00)01902-7

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  69 in total

1.  Poly(ADP-ribose) polymerase 1 and Ste20-like kinase hKFC act as transcriptional repressors for gamma-2 herpesvirus lytic replication.

Authors:  Yousang Gwack; Hiroyuki Nakamura; Sun Hwa Lee; John Souvlis; Jason T Yustein; Steve Gygi; Hsing-Jien Kung; Jae U Jung
Journal:  Mol Cell Biol       Date:  2003-11       Impact factor: 4.272

Review 2.  Deadly conversations: nuclear-mitochondrial cross-talk.

Authors:  Valina L Dawson; Ted M Dawson
Journal:  J Bioenerg Biomembr       Date:  2004-08       Impact factor: 2.945

Review 3.  NAD+ depletion or PAR polymer formation: which plays the role of executioner in ischaemic cell death?

Authors:  C Siegel; L D McCullough
Journal:  Acta Physiol (Oxf)       Date:  2011-01-19       Impact factor: 6.311

4.  Inhibition of nicotinamide phosphoribosyltransferase: cellular bioenergetics reveals a mitochondrial insensitive NAD pool.

Authors:  Maria Pittelli; Laura Formentini; Giuseppe Faraco; Andrea Lapucci; Elena Rapizzi; Francesca Cialdai; Giovanni Romano; Gloriano Moneti; Flavio Moroni; Alberto Chiarugi
Journal:  J Biol Chem       Date:  2010-08-19       Impact factor: 5.157

Review 5.  Parthanatos: mitochondrial-linked mechanisms and therapeutic opportunities.

Authors:  Amos A Fatokun; Valina L Dawson; Ted M Dawson
Journal:  Br J Pharmacol       Date:  2014-04       Impact factor: 8.739

6.  The macro domain is an ADP-ribose binding module.

Authors:  Georgios I Karras; Georg Kustatscher; Heeran R Buhecha; Mark D Allen; Céline Pugieux; Fiona Sait; Mark Bycroft; Andreas G Ladurner
Journal:  EMBO J       Date:  2005-05-19       Impact factor: 11.598

7.  Shear stress, SIRT1, and vascular homeostasis.

Authors:  Zhen Chen; I-Chen Peng; Xiaopei Cui; Yi-Shuan Li; Shu Chien; John Y-J Shyy
Journal:  Proc Natl Acad Sci U S A       Date:  2010-05-17       Impact factor: 11.205

Review 8.  Mitochondrial dysfunction and NAD(+) metabolism alterations in the pathophysiology of acute brain injury.

Authors:  Katrina Owens; Ji H Park; Rosemary Schuh; Tibor Kristian
Journal:  Transl Stroke Res       Date:  2013-08-10       Impact factor: 6.829

9.  Functional localization of two poly(ADP-ribose)-degrading enzymes to the mitochondrial matrix.

Authors:  Marc Niere; Stefan Kernstock; Friedrich Koch-Nolte; Mathias Ziegler
Journal:  Mol Cell Biol       Date:  2007-11-08       Impact factor: 4.272

10.  PARP inhibition delays progression of mitochondrial encephalopathy in mice.

Authors:  Roberta Felici; Leonardo Cavone; Andrea Lapucci; Daniele Guasti; Daniele Bani; Alberto Chiarugi
Journal:  Neurotherapeutics       Date:  2014-07       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.